Eisai Co., Ltd. (TYO:4523)
Japan
· Delayed Price · Currency is JPY 4,821.00
-39.00 (-0.80%)
At close: Mar 9, 2026
Eisai Employees
Eisai had 10,917 employees as of March 31, 2025. The number of employees decreased by 150 or -1.36% compared to the previous year.
Employees
10,917
Change (1Y)
-150
Growth (1Y)
-1.36%
Revenue / Employee
74.03M JPY
Profits / Employee
3.92M JPY
Market Cap
1,359.00B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Sumitomo Pharma | 3,832 |
| Shionogi & | 4,955 |
| Hisamitsu Pharmaceutical Co. | 2,799 |
| Nippon Shinyaku | 2,243 |
| Toho Holdings | 7,609 |
| Tsumura & Co. | 4,272 |
| Sawai Group Holdings | 3,310 |
| Takeda Pharmaceutical Company | 47,455 |
Eisai News
- 25 days ago - Q3 2026 Eisai Co Ltd Earnings Presentation Transcript - GuruFocus
- 4 weeks ago - Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan - PRNewsWire
- 4 weeks ago - Eisai strikes Japan licensing deal with Shanghai Henlius Biotech - Reuters
- 3 months ago - Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 - PRNewsWire
- 3 months ago - Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025 - PRNewsWire
- 3 months ago - Eisai to Present Data on Lecanemab Continued Treatment, Subcutaneous Initiation Dosing, and Real-World Experience at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference - PRNewsWire
- 4 months ago - Merck, Eisai discontinue late-stage study for liver cancer therapy - Reuters
- 4 months ago - Merck-Eisai's cancer drug combo meets one main goal in late-stage study - Reuters